Habitat: Native to Europe; found as an escape in some parts of Kashmir.
English: Tansy.Folk: Peilmundi (Kashmir).Action: Plant—anthelmintic, bitter tonic, emmenagogue. Used for migraine, neuralgia and nausea; as a lotion for scabies. Toxicity depends upon thujone content of the part used. Tansy oil is used as a liniment for gout and rheumatism.
Aerial parts afforded terpenoids— tanacetin, vulgarones A and B, tamirin, tanacin and tanavulgarol; germacano- lides, stearic acid, and flavonoids— apigenin trimethyl ether, apigenin, luteolin, chrysoeriol, diometin, iso- rhamnetin, quercetin and axillarin. The leaves contain parthenolide, caffe- ic, chlorogenic, iso-chlorogenic acids and vibernitol.Indian chemotype contains beta- thujone (28.1%) as the major constituent of the essential oil. Other constituents are: beta-thujyl alcohol 8.7, /-camphor 10.0 and cineol 11.8%. The leaves contain parthenolide, caf- feic, chlorogenic, isochlorogenic acid and vibernitol.Tanacetum parthenium (L.) Schultz Bip. (native to Europe and British Isles), known as Feverfew, is available in India for prophylactic treatment of migraine. The characteristic constituents of the herb (dried, whole or fragmented parts) are sesquiterpene lactones of which parthenolide, a ger- macanolide, is the major component. (Indian species, T. vulgare leaf also contains parthenolide).ESCOP recommends the herb for the management of migraine for at least a few months.(See ESCOP and WHO monographs.)It has been shown that Feverfew extract inhibits prostaglandin production and arachidonic acid release (this activity, at least partly, explains the herb's antiplatelet and antifebrile action). The extracts also inhibit secretion of serotonin from platelet granules and proteins from polymorphonuclear leucocytes (PMN's). Since serotonin is implicated in the aetiology of migraine and PMN secretion is increased in rheumatoid arthritis. Feverfew is used in migraine and rheumatoid arthritis. (Potter's New Cyclopaedia.) Somehow, beneficial effects were not observed in a double-blind placebo-controlled trial on 40 women with rheumatoid arthritis. (WHO.)